Showing 43,741 - 43,760 results of 113,932 for search '(( 5 ((a decrease) OR (mean decrease)) ) OR ( a ((fold decrease) OR (point decrease)) ))', query time: 1.45s Refine Results
  1. 43741
  2. 43742

    Costs and effectiveness of pharmacist-led group medical visits for type-2 diabetes: A multi-center randomized controlled trial by Wen-Chih Wu (352695)

    Published 2018
    “…</p><p>Trial registration</p><p><a href="https://clinicaltrials.gov/ct2/show/NCT00554671" target="_blank">NCT00554671</a> ClinicalTrials.gov</p></div>…”
  3. 43743
  4. 43744
  5. 43745
  6. 43746
  7. 43747
  8. 43748

    Mdm2 is involved in the maintenance of mitochondrial biogenesis and bioenergetics. by Ludger Hauck (4277884)

    Published 2017
    “…<p>(A) Expression levels of selected factors from top-ranked gene sets identified in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0189861#pone.0189861.g004" target="_blank">Fig 4A</a> that play a crucial role in the regulation of mitochondrial function and fatty acid oxidation as analyzed by RT-qPCR. …”
  9. 43749
  10. 43750

    CONSORT flow diagram. by Rachel M. Radin (6689855)

    Published 2023
    “…</p><p><b>Trial registration: Clinical trial registration</b><a href="http://www.clinicaltrials.gov/" target="_blank">http://www.ClinicalTrials.gov</a>: identifier <a href="https://clinicaltrials.gov/ct2/show/NCT03945214" target="_blank">NCT03945214</a>.…”
  11. 43751

    Baseline demographics. by Rachel M. Radin (6689855)

    Published 2023
    “…</p><p><b>Trial registration: Clinical trial registration</b><a href="http://www.clinicaltrials.gov/" target="_blank">http://www.ClinicalTrials.gov</a>: identifier <a href="https://clinicaltrials.gov/ct2/show/NCT03945214" target="_blank">NCT03945214</a>.…”
  12. 43752

    Baseline health characteristics. by Rachel M. Radin (6689855)

    Published 2023
    “…</p><p><b>Trial registration: Clinical trial registration</b><a href="http://www.clinicaltrials.gov/" target="_blank">http://www.ClinicalTrials.gov</a>: identifier <a href="https://clinicaltrials.gov/ct2/show/NCT03945214" target="_blank">NCT03945214</a>.…”
  13. 43753
  14. 43754

    Stoichiometry, polarity, and organometallics in solid-phase extracted dissolved organic matter of the Elbe-Weser estuary by Kerstin B. Ksionzek (5721182)

    Published 2018
    “…<div><p>Dissolved organic matter (DOM) is ubiquitous in natural waters and plays a central role in the biogeochemistry in riverine, estuarine and marine environments. …”
  15. 43755

    WIN reduced bone resorption and MMP-9-activity in a capsaicin sensitive manner. by Svantje Tauber (121637)

    Published 2012
    “…Additional treatment with capsaicin (CIC) antagonized this decrease. Data are shown as means +/− SD, n = 5. (b) MMP-9-activity-ELISA of conditioned medium of osteoclasts. …”
  16. 43756

    Scenarios analysed. by Joachim Worthington (8394213)

    Published 2024
    “…Modelling was used to estimate short- and long-term effects on colorectal cancer incidence and mortality, including ongoing impact of patient backlogs. A hypothetical mitigation strategy was simulated, with diagnostic and treatment capacities increased by 5% from 2022 to address backlogs. …”
  17. 43757

    Post- diagnosis CRC survival model (Australia). by Joachim Worthington (8394213)

    Published 2024
    “…Modelling was used to estimate short- and long-term effects on colorectal cancer incidence and mortality, including ongoing impact of patient backlogs. A hypothetical mitigation strategy was simulated, with diagnostic and treatment capacities increased by 5% from 2022 to address backlogs. …”
  18. 43758

    Model outputs used to inform this study. by Joachim Worthington (8394213)

    Published 2024
    “…Modelling was used to estimate short- and long-term effects on colorectal cancer incidence and mortality, including ongoing impact of patient backlogs. A hypothetical mitigation strategy was simulated, with diagnostic and treatment capacities increased by 5% from 2022 to address backlogs. …”
  19. 43759

    Phenotypic and genotypic analysis following treatment of incrossed heterozygous <i>bmp4</i><sup><i>st72/+</i></sup> zebrafish with 0 μM, 0.25 μM and 0.5 μM PTC124. by Max Krall (6631025)

    Published 2019
    “…Error bars show standard error of the mean. We tested for trend in the probability of tail fin defects across the increasing doses of 0 μM, 0.25 μM and 0.5 μM PTC124 treated, groups of homozygous larvae [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0212121#pone.0212121.ref024" target="_blank">24</a>]. …”
  20. 43760